Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
This study has been completed.
Sponsor:
University of Utah
Collaborator:
MXI Corporation
Information provided by:
University of Utah
ClinicalTrials.gov Identifier:
NCT00666250
First received: April 22, 2008
Last updated: April 23, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
An antioxidant dietary supplement made from cocoa powder, and extracts of acai, grape and blueberry will be tested for effects on blood sugar, blood pressure, cholesterol and related parameters in human subjects.
| Condition | Intervention |
|---|---|
|
Hypertension Dyslipidemia Hyperglycemia |
Dietary Supplement: Xocai Activ drink |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind (Investigator) Primary Purpose: Prevention |
| Official Title: | Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors |
Resource links provided by NLM:
MedlinePlus related topics:
Antioxidants
Atherosclerosis
Diabetes Medicines
Dietary Supplements
High Blood Pressure
Hyperglycemia
U.S. FDA Resources
Further study details as provided by University of Utah:
Primary Outcome Measures:
- Blood pressure [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Plasma Lipids [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- Arterial Compliance [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- Fasting and post-challenge glucose and insulin [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
- urine microalbumin/creatinine ratio [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
| Enrollment: | 10 |
| Study Start Date: | January 2006 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Baseline
Baseline values off chocolate supplement
|
|
|
Experimental: Low Dose
Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
|
Dietary Supplement: Xocai Activ drink
proprietary blend of cocoa powder and extracts of acai, grape and blueberry
Other Names:
|
|
Experimental: High-dose
High dose of dietary supplement 90 ml tid (Xocai Activ drink)
|
Dietary Supplement: Xocai Activ drink
proprietary blend of cocoa powder and extracts of acai, grape and blueberry
Other Names:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- healthy adult not taking cocoa supplements
Exclusion Criteria:
- diabetes mellitus
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00666250
Locations
| United States, Utah | |
| Cardiovascular Genetics, University of Utah | |
| Salt Lake City, Utah, United States, 84108 | |
Sponsors and Collaborators
University of Utah
MXI Corporation
Investigators
| Principal Investigator: | Eliot Brinton, MD | University of Utah |
More Information
Additional Information:
No publications provided
| Responsible Party: | Eliot A. Brinton, Cardiovascular Genetics, University of Utah |
| ClinicalTrials.gov Identifier: | NCT00666250 History of Changes |
| Other Study ID Numbers: | Xocai01 |
| Study First Received: | April 22, 2008 |
| Last Updated: | April 23, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Utah:
|
blood pressure dyslipidemia hyperglycemia |
Additional relevant MeSH terms:
|
Atherosclerosis Hyperglycemia Hypertension Dyslipidemias Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases |
Glucose Metabolism Disorders Metabolic Diseases Lipid Metabolism Disorders Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013